Existing partnerships

We partner with like-minded organisations to improve the lives of patients with chronic disease.

We work collaboratively with our partners to develop and create value added products for patients, health care professionals and health systems.

Partnership opportunities

Curebase

Development partner

CureBase has developed a full eClinical suite from the ground up, purpose-built for decentralised research. Closed Loop Medicine and Curebase partnered on the delivery of a decentralised clinical trial in the US during the COVID-19 pandemic for patients with hypertension.

The data generated from this study will be used to better understand the relationship between high blood pressure and COVID-19 as well as provide insights on disease management solutions.

Innovate UK

Development partner

Innovate UK is part of UK Research and Innovation (UKRI) the national funding agency investing in science and research in the UK. Closed Loop Medicine secured multiple rounds of grant funding from Innovate UK through the Innovate UK Precision Medicine Innovation Accelerator to support clinical research in precision care solutions for high blood pressure.

NorthWest EHealth

Development partner

NorthWest EHealth are world leaders in the innovative and trustworthy use of routinely collected healthcare data for clinical trials. Closed Loop Medicine partnered with NorthWest EHealth for a retrospective real-world ethics-approved patient cohort study, a data extraction was undertaken from a proprietary 2.5m patient population in Greater Manchester. As well as the population level data analysis, health records of a subset of patients were analysed to better understand constraints and logic in clinical care and decision making.

Orient Pharma

Development partner

Orient Pharma is an R&D and manufacturing company based in Taiwan. Orient and Closed Loop Medicine have formed a strategic partnership for the development of novel drug + digital combination products. Orient Pharma are our key delivery partner in the development of the drug component of CLMIN01.

uMed

Development partner

uMed is a technology platform embedded within a global network of healthcare providers that automates the process of building high quality prospective research registries. Working with uMed, Closed Loop Medicine have been able to expand the reach and efficiency of a pivotal clinical study for patients with hypertension. The relationship embodies the future of how both clinical trials will be run and care delivered – decentralised.

Queen Mary University London, The William Harvey Research Institute – Barts and The London School of Medicine and Dentistry

Clinical Academic Partner

The William Harvey Research Institute is an internationally acknowledged centre of excellence in the field of cardiovascular research. Together we are conducting a novel PhIV precision medicine interventional clinical trial for patients with high blood pressure. The clinical trial will see up to 1,000 patients recruited for a study investigating whether a combination product that links a drug to a smart phone app can enable patients to personalise and optimise their therapy regimen to treat hypertension.

We work collaboratively with our partners to develop and create value added products for patients, health care professionals and health systems.

Partnership opportunities

Curebase

Development partner

CureBase has developed a full eClinical suite from the ground up, purpose-built for decentralised research. Closed Loop Medicine and Curebase partnered on the delivery of a decentralised clinical trial in the US during the COVID-19 pandemic for patients with hypertension.

The data generated from this study will be used to better understand the relationship between high blood pressure and COVID-19 as well as provide insights on disease management solutions.

Innovate UK

Development partner

Innovate UK is part of UK Research and Innovation (UKRI) the national funding agency investing in science and research in the UK. Closed Loop Medicine secured multiple rounds of grant funding from Innovate UK through the Innovate UK Precision Medicine Innovation Accelerator to support clinical research in precision care solutions for high blood pressure.

NorthWest EHealth

Development partner

NorthWest EHealth are world leaders in the innovative and trustworthy use of routinely collected healthcare data for clinical trials. Closed Loop Medicine partnered with NorthWest EHealth for a retrospective real-world ethics-approved patient cohort study, a data extraction was undertaken from a proprietary 2.5m patient population in Greater Manchester. As well as the population level data analysis, health records of a subset of patients were analysed to better understand constraints and logic in clinical care and decision making.

Orient Pharma

Development partner

Orient Pharma is an R&D and manufacturing company based in Taiwan. Orient and Closed Loop Medicine have formed a strategic partnership for the development of novel drug + digital combination products. Orient Pharma are our key delivery partner in the development of the drug component of CLMIN01.

uMed

Development partner

uMed is a technology platform embedded within a global network of healthcare providers that automates the process of building high quality prospective research registries. Working with uMed, Closed Loop Medicine have been able to expand the reach and efficiency of a pivotal clinical study for patients with hypertension. The relationship embodies the future of how both clinical trials will be run and care delivered – decentralised.

Queen Mary University London, The William Harvey Research Institute – Barts and The London School of Medicine and Dentistry

Clinical Academic Partner

The William Harvey Research Institute is an internationally acknowledged centre of excellence in the field of cardiovascular research. Together we are conducting a novel PhIV precision medicine interventional clinical trial for patients with high blood pressure. The clinical trial will see up to 1,000 patients recruited for a study investigating whether a combination product that links a drug to a smart phone app can enable patients to personalise and optimise their therapy regimen to treat hypertension.

What they say about us

From the day of their first approach to us, we formed a close working relationship with the team from Closed Loop Medicine. The work has been stimulating. It’s all centred on finding the right treatment regime for each individual patient, centred on outcomes and personalised care.

Dr David Collier
Clinical Director, Queen Mary University London

CPI has core strengths in healthcare innovation and we were delighted to collaborate with Closed Loop Medicine on the next step towards more patient centric healthcare innovation, one that links traditional therapeutics, medical devices and digital health.

Arun Harish PhD MBA
Strategy Director, CPI

Closed Loop Medicine are pioneering the next generation of therapeutic products, one that links remote monitoring with intervention. At uMed we saw the potential to combine our unique approach to clinical trial delivery with Closed Loop Medicine to initiate an exciting decentralised clinical trial in partnership.

Matt Wilson
CEO, uMed

It has been refreshing to engage with the Closed Loop Medicine team. They proactively engaged the Association of Medical Research Charities early to encourage partnerships with research charities and involve patients in product and trial design.

Carol Bewick
Association of Medical Research Charities

Latest news

Press releases

Closed Loop Medicine closes £13 million to finance its personalised drug + digital therapy (DTx) combination products to improve outcomes for patients through precision dosing.

Press releases

Closed Loop Medicine announces positive outcome of a key clinical drug study required for regulatory submission of its ‘drug plus digital’ insomnia product CLM-IN01.

Press releases

Closed Loop Medicine secures UKCA marking and receives CE designation for a Medical Device that will form part of its insomnia product CLM-IN01

Press releases

Closed Loop Medicine closes £13 million to finance its personalised drug + digital therapy (DTx) combination products to improve outcomes for patients through precision dosing.

Press releases

Closed Loop Medicine announces positive outcome of a key clinical drug study required for regulatory submission of its ‘drug plus digital’ insomnia product CLM-IN01.

Press releases

Closed Loop Medicine secures UKCA marking and receives CE designation for a Medical Device that will form part of its insomnia product CLM-IN01